Sartorius Financial Statements From 2010 to 2025
| SDMHF Stock | USD 195.00 0.00 0.00% |
Check Sartorius Stedim financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sartorius Stedim's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sartorius financial statements analysis is a perfect complement when working with Sartorius Stedim Valuation or Volatility modules.
Sartorius |
Sartorius Stedim Biotech Company Return On Equity Analysis
Sartorius Stedim's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sartorius Stedim Return On Equity | 0.33 |
Most of Sartorius Stedim's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sartorius Stedim Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Sartorius Stedim Biotech has a Return On Equity of 0.3306. This is 101.38% lower than that of the Healthcare sector and 105.53% lower than that of the Medical Instruments & Supplies industry. The return on equity for all United States stocks is notably lower than that of the firm.
Sartorius Stedim Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sartorius Stedim's current stock value. Our valuation model uses many indicators to compare Sartorius Stedim value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sartorius Stedim competition to find correlations between indicators driving Sartorius Stedim's intrinsic value. More Info.Sartorius Stedim Biotech is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sartorius Stedim Biotech is roughly 2.38 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sartorius Stedim's earnings, one of the primary drivers of an investment's value.About Sartorius Stedim Financial Statements
Sartorius Stedim stakeholders use historical fundamental indicators, such as Sartorius Stedim's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sartorius Stedim investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sartorius Stedim's assets and liabilities are reflected in the revenues and expenses on Sartorius Stedim's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sartorius Stedim Biotech. Please read more on our technical analysis and fundamental analysis pages.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. Sartorius Stedim operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 10409 people.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Sartorius Pink Sheet
Sartorius Stedim financial ratios help investors to determine whether Sartorius Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.